^
BIOMARKER:

BCR-ABL1 fusion

i
Other names: BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL, ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1
Entrez ID:
BCR-ABL1 fusion
CML
imatinib
Sensitive: A1 - Approval
Cureus - 3 weeks
BCR-ABL1 fusion
CML
dasatinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
imatinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
ponatinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
dasatinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
nilotinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
bosutinib
Sensitive: A1 - Approval
BCR-ABL1 fusion
ALL
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
bosutinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
inotuzumab ozogamicin
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: A2 - Guideline
BCR-ABL1 fusion
CML
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
Tyrosine kinase inhibitor
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
ALL
etoposide IV
Sensitive: B - Late Trials
BCR-ABL1 fusion
CML
ABL001
Sensitive: B - Late Trials
BCR-ABL1 fusion
CML
ponatinib
Sensitive: C1 - Off-label
BCR-ABL1 fusion
ALL
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
ALL
CVAD + Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
ALL
ponatinib + blinatumomab
Sensitive: C3 – Early Trials
BCR-ABL1 fusion
MDS
imatinib
Sensitive: C4 – Case Studies
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: C4 – Case Studies
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib + blinatumomab
Sensitive: C4 – Case Studies
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
S63845 + S55746
Sensitive: D – Preclinical
BCR-ABL1 fusion
CML
ponatinib + GMX1778
Sensitive: D – Preclinical
BCR-ABL1 fusion
ALL
KPT-8602
Sensitive: D – Preclinical
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + nilotinib + YD312 + S81694
Sensitive: D – Preclinical
BCR-ABL1 fusion
CML
ponatinib + CUDC-907
Sensitive: D – Preclinical
BCR-ABL1 fusion
ALL
olaparib
Sensitive: D – Preclinical
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + JNK-IN-8
Sensitive: D – Preclinical
BCR-ABL1 fusion
ALL
aminoxyrone
Sensitive: D – Preclinical
BCR-ABL1 fusion
ALL
venetoclax + dasatinib
Sensitive: D – Preclinical